Welcome to our dedicated page for OPA.U news (Ticker: OPA.U), a resource for investors and traders seeking the latest updates and insights on OPA.U stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OPA.U's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OPA.U's position in the market.
Magnum Opus Acquisition Limited announced that beginning May 14, 2021, holders of its IPO units (20,000,000 units from March 25, 2021) can opt to separately trade Class A ordinary shares and warrants. The remaining units will trade under the symbol OPA.U, while separated shares and warrants will trade under OPA and OPA WS respectively. This separation allows investors more flexibility in trading their holdings. The offering is represented by Credit Suisse Securities (USA) LLC, and relevant prospectus is available through them.
Magnum Opus Acquisition Limited announced the pricing of its IPO, offering 20 million units at $10.00 each, expected to trade on NYSE under symbol 'OPA.U' starting March 23, 2021. Each unit comprises a Class A ordinary share and a half warrant, with whole warrants exercisable at $11.50 per share. The company aims to identify targets in consumer, technology, and media sectors that leverage technology for growth, particularly in Asia. The offering also allows underwriters a 45-day option for an additional 3 million units. The IPO closes on March 25, 2021, pending conditions.
